University of Southampton
Investigating the role of RALY-AS1 in the CCL3/CCR5/RALY pathway
Abstract
dc:description.abstractMacrophages are important innate immune cells responsible for a variety of functions including phagocytosis, antigen presentation and the activation of other immune cells. These actions are important in dealing with pathogens, such as bacteria and viruses, and tumour cells, but also have anti-inflammatory properties through wound healing and angiogenesis. CCL3 is a chemokine secreted by immune cells, such as macrophages and NK cells, which recruits macrophages to affected tissues by chemotaxis. CCL3 attracts immune cells through binding to CCR5, which is a G protein coupled receptor expressed on the surface of immune cells such as T cells and other macrophages. One regulating factor that is known to influence the CCR5/CCL3 axis is the RNA binding protein RALY. RALY is able to bind and degrade CCR5 mRNA in T cells which downregulates the receptors available to respond to the CCL3 protein secreted by macrophages. Interestingly, the reverse genomic strand of RALY encodes for an antisense RNA called RALY-AS1. Antisense RNAs are long non-coding RNAs which are transcribed from the reverse strand of DNA and are complementary to a protein coding mRNA. Antisense RNAs have been shown to play an important role in gene expression which can occur through several different mechanisms including the recruitment of enhancer proteins or acting as a molecular sponge for mRNA degrading miRNAs. The precise mechanism of RALY-AS1 is still not characterised.<br/>Our hypothesis was that RALY-AS1 plays a role in how RALY regulates the CCL3/CCR5 pathway. Such a role may have an impact in the regulation of the chemotaxis of immune cells and on the immune response to pathogens and cancer, with significant clinical consequences. To validate our hypothesis, a model was created to observe cell function, such as CCL3 expression, when RALY-AS1 expression was downregulated. This was done in model THP-1 cells using siRNA targeting RALY-AS1 to knock down its expression. When RALY-AS1 expression was reduced, we observed that the expression of CCL3, as well as other chemokines, decreased at both the mRNA and protein level, determined through qPCR and ELISA. These results suggested that RALY-AS1 was enhancing the expression of this chemokine. RNA-seq of the samples revealed that there were at least six different transcripts of RALY-AS1 present in THP-1 cells. To confirm the role of RALY-AS1 on these chemokines, lentivirus was used to generate a model which overexpressed one of the transcripts of RALY-AS1 which was termed Transcript 1. Rather than showing the predicted increase in chemokine levels, a decrease in chemokines was seen when Transcript 1 of RALY-AS1 was overexpressed.<br/> As overexpressing Transcript 1 and knocking down multiple RALY-AS1 transcripts both resulted in a decrease in cytokine expression, it was determined that it was likely that different RALY-AS1 transcripts had different mechanisms which both influenced the expression of chemokines. CLIP-seq has previously demonstrated that RALY-AS1 is able to bind to miRNA hsa-let-7b-5p and this miRNA is predicted to be able to bind to CCL3 mRNA. Therefore, one of the proposed mechanisms for how RALY-AS1 regulates CCL3 expression is that an undetermined transcript of RALY-AS1 is able to act as a molecular sponge for miRNAs that target CCL3 mRNA. The protein RALY was shown to bind to RALY-AS1 and the mRNAs of the chemokines. RALY-AS1 is likely altering how RALY is able to interact with these mRNAs either by strengthening the interaction if RALY is degrading the mRNAs or by inhibiting the interaction if RALY is stabilising the mRNAs.<br/>The CCL3/CCR5 pathway is vital for macrophage function so understanding how all the unique components interact allows for therapeutic interventions to be developed. As CCL3 overexpression is correlated with poor prognosis in some cancers, being able to dampen the effects of the pathway could lead to improved patient outcomes. Designing drugs to regulate RALY-AS1’s mode of action could have the potential for a new set of drugs to regulate macrophage action with our work suggesting that these drugs will have to be precisely designed to avoid targeting an unwanted transcript of RALY-AS1. The methods and findings reported in this project could be applicable in investigating the role and mechanism of other antisense RNAs.<br/>
Degree
thesis:*- Name dc:type.qualificationname
- Ph.D.
- Level dc:type.qualificationlevel
- doctoral
- Grantor dc:publisher.institution
- University of Southampton
- Year dc:date.issued
- 2026
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Johnson, Connor Benjamin
- Advisors dc:contributor.advisor
-
- Sanchez-Elsner, Tilman
- Vorobeva, Elena Vladimirovna
- Mansour, Salah
- Roghanian, Ali
- ORCID person:identifier.orcid
Rights
- Language dc:language
- English, eng
Identifiers
dc:identifier.*- DOI dc:identifier.doi
- https://doi.org/10.5258/SOTON/01/T111